Summary Slide.png (124.54 kB)

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-To-Severe Psoriasis: Long-Term Results From the UNCOVER-1 and UNCOVER-2 Phase 3 Randomized Controlled Trials

figure

posted on 2020-03-18, 11:24 authored by Craig Leonardi, Kristian Reich, Peter Foley, Hideshi Torii, Sascha Gerdes, Lyn Guenther, Melinda Gooderham, Laura Ferris, Christopher E.M. Griffiths, Hany Elmaraghy, Heidi Crane, Himanshu Patel, Russel Burge, Gaia Gallo, David Shrom, Ann Leung, Cheng-Yen Lin, Kim Papp

Provide enhanced digital features for this article

This Figshare page contains a Summary Slide. If you are an author of this publication and would like to provide additional enhanced digital features for your article then please contact adisrapidplus@springer.com.

The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.

Other enhanced features include, but are not limited to:
• Slide decks
• Videos and animations
• Audio abstracts
• Audio slides